Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells

Jiang,Lu; Chen,Yongchang; Sang,Jianrong; Li,Yueying; Lan,Ting; Wang,Ying; Tao,Yan; Qian,Hai

doi:10.3892/br.2013.85

Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells

Authors:
- Lu Jiang
- Yongchang Chen
- Jianrong Sang
- Yueying Li
- Ting Lan
- Ying Wang
- Yan Tao
- Hai Qian
View Affiliations

Affiliations: Department of Physiology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China
Published online on: March 21, 2013 https://doi.org/10.3892/br.2013.85
Pages: 399-404

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Receptor tyrosine kinases (RTKs) are key to the regulation of biological cell activities, particularly of tumor cells. In a previous study, we demonstated that type II cGMP‑dependent protein kinase (PKG II) may inhibit the activation of epidermal growth factor receptor (EGFR), a key member of the RTK family, and inhibit the consequent signal transduction in gastric cancer cells. Since RTKs exhibit a high level of conservation in their molecular structure, we hypothesized that PKG II may exert a similar inhibitory effect on the activation of other members of the RTK family. The aim of the present study was to investigate the potential inhibitory effect of PKG II on the activation of vascular endothelial growth factor receptor (VEGFR), platelet‑derived growth factor receptor (PDGFR) and insulin‑like growth factor‑1 receptor (IGF‑1R). The AGS gastric cancer cell line was transfected with adenoviral vector encoding PKG II cDNA (Ad‑PKG II) to increase the expression of PKG II and incubated with 8‑pCPT‑cGMP to activate the kinase. The cells were then stimulated with VEGF, PDGF and IGF‑1, and the phosphorylation/activation of relative RTKs was detected by western blot analysis. The results demonstrated that stimulating cells with VEGF‑C (100 ng/ml), PDGF‑BB (100 ng/ml) and IGF‑1 (100 ng/ml) for 5 min led to a clear increase of phosphorylation of VEGFR2 (Tyr 951), PDGFRβ (Tyr 751) and IGF‑1R (Tyr 1161), respectively. Pre‑infection of the cells with Ad‑PKG II with a multiplicity of infection (MOI) of 100% overnight and pre‑incubation of cells with 8‑pCPT‑cGMP (100 and 250 µM) for 1 h efficiently inhibited the ligand‑binding‑induced phosphorylation/activation of the RTKs. PKG II also inhibited the MAPK/ERK‑ and PI3K‑mediated signal transductions induced by VEGF‑C, PDGF‑BB and IGF‑1. The results demonstrated that PKG II may exert a wide range of inhibitory effects on the activation of RTKs and provided further evidence to confirm PKG II as a tumor suppressor.

View Figures

View References

1	Robinson DR, Wu YM and Lin SF: The protein tyrosine kinase family of the human genome. Oncogene. 19:5548–5557. 2000. View Article : Google Scholar : PubMed/NCBI
2	Zwick E, Bange J and Ullrich A: Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI
3	Lemmon MA and Schlessinger J: Cell signaling by receptor-tyrosine kinases. Cell. 141:1117–1134. 2010. View Article : Google Scholar : PubMed/NCBI
4	Choura M and Rebaï A: Receptor tyrosine kinases: from biology to pathology. J Recept Signal Transduct Res. 31:387–394. 2011. View Article : Google Scholar : PubMed/NCBI
5	Zhang H, Berezov A, Wang Q, et al: ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 117:2051–2058. 2007. View Article : Google Scholar : PubMed/NCBI
6	Stuttfeld E and Ballmer-Hofer K: Structure and function of VEGF receptors. IUBMB Life. 61:915–922. 2009. View Article : Google Scholar
7	Holmes K, Roberts OL, Thomas AM and Cross MJ: Vascular endothelial growth factor receptor-2: structure, function, intra-cellular signalling and therapeutic inhibition. Cell Signal. 19:2003–2012. 2007. View Article : Google Scholar
8	Suzuki S, Dobashi Y, Hatakeyama Y, et al: Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer. BMC Cancer. 30:659–668. 2010.PubMed/NCBI
9	Hartog H, Wesseling J, Boezen HM and van der Graaf WT: The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer. 43:1895–1904. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ouban A, Muraca P, Yeatman T and Coppola D: Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 34:803–808. 2003. View Article : Google Scholar : PubMed/NCBI
11	Cook AL and Haynes JM: Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal. 16:253–261. 2004. View Article : Google Scholar : PubMed/NCBI
12	Cook AL and Haynes JM: Phosphorylation of the PKG substrate, vasodilator-stimulated phosphoprotein (VASP), in human cultured prostatic stromal cells. Nitric Oxide. 16:10–17. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chiche JD, Schlutsmeyer SM, Bloch DB, et al: Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem. 273:34263–34271. 1998. View Article : Google Scholar
14	Hood J and Granger HJ: Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J Biol Chem. 273:23504–23508. 1998. View Article : Google Scholar : PubMed/NCBI
15	Swartling FJ, Ferletta M, Kastemar M, et al: Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene. 28:3121–3131. 2009. View Article : Google Scholar : PubMed/NCBI
16	Wang R, Kwon IK, Thangaraju M, et al: Type 2 cGMP-dependent protein kinase regulates proliferation and differentiation in the colonic mucosa. Am J Physiol Gastrointest Liver Physiol. 303:G209–G219. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yang SQ, Chen YC, Wang Y, et al: Expression of cGMP dependent protein kinase II in cancer cell lines was obviously decreased. J Jiangsu Univ (Medicine edition). 18:1–5. 2008.
18	Chen YC, Ren F, Sang JR, et al: Type II cGMP-dependent protein kinase inhibits proliferation of the gastric cancer cell line BGC-823. Mol Med Rep. 3:361–366. 2010.PubMed/NCBI
19	Wu Y, Chen Y, Qu R, et al: Type II cGMP-dependent protein kinase inhibits EGF-triggered signal transduction of the MAPK/ERK-mediated pathway in gastric cancer cells. Oncol Rep. 27:553–558. 2010.PubMed/NCBI
20	Lan T, Chen Y, Sang J, et al: Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK/JNK signal transduction in breast cancer cells. Oncol Rep. 27:2039–2044. 2012.PubMed/NCBI
21	Fournier NM, Lee B, Banasr M, et al: Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling. Neuropharmacology. 63:642–652. 2012. View Article : Google Scholar : PubMed/NCBI
22	Pratsinis H and Kletsas D: PDGF, bFGF and IGF-I stimulate the proliferation of intervertebral disc cells in vitro via the activation of the ERK and Akt signaling pathways. Eur Spine J. 16:1858–1866. 2007. View Article : Google Scholar : PubMed/NCBI
23	Quatrale AE, Porcelli L, Silvestris N, et al: EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci. 16:1962–1972. 2011. View Article : Google Scholar : PubMed/NCBI
24	Normanno N, Bianco C, De Luca A, et al: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI
25	Oda K, Matsuoka Y, Funahashi A and Kitano H: A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 1:2005.00102005.PubMed/NCBI
26	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1127. 2005. View Article : Google Scholar : PubMed/NCBI
27	Gretschel S, Astrosini C, Vieth M, et al: Markers of tumor angiogenesis and tumor cells in bone marrow in gastric cancer patients. Eur J Surg Oncol. 34:642–647. 2008. View Article : Google Scholar : PubMed/NCBI
28	Koch S and Claesson-Welsh L: Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2:a0065022012. View Article : Google Scholar : PubMed/NCBI
29	Heldin CH: Structural and functional studies on platelet-derived growth factor. EMBO J. 11:4251–4259. 1992.PubMed/NCBI
30	Li ZF, Su YF and Chen XP: Expression of platelet-derived growth factor receptor in hepatocellular carcinoma and portal vein tumor thrombus. Acta Academiae Medicinae Qingdao Universitatis. 44:307–311. 2008.(In Chinese).
31	Luo HG, Ding YW, Ma TX, et al: Study on the correlation between flt-1, bFGFR, PDGFR and tumor biology in pancreatic carcinoma. Zhonghua Xiao Hua Wai Ke Za Zhi. 1:253–255. 2002.(In Chinese).
32	Zhu HT, Han J and Ma L: Expression and clinical significance of PDGFRalpha and PDGFRbeta in colorectal cancer. Ai Zheng. 27:654–660. 2008.(In Chinese).
33	Liu DC, Li RG, Zhou JP, et al: Relationship between the expression of PDGF and PDGFR and MVC in the gastric carcinoma. Zhongguo Lin Chuang Yi Sheng. 5:1061–1062. 2003.(In Chinese).
34	Board R and Jayson GC: Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat. 8:75–83. 2005. View Article : Google Scholar : PubMed/NCBI
35	Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 16:3–34. 1995.PubMed/NCBI
36	Neid M, Datta K, Stephan S, et al: Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J Biol Chem. 279:3941–3948. 2004. View Article : Google Scholar